Topic: treatment-resistant tumors
Tyra Biosciences raised $50 million to develop a pipeline of “very specific” small molecules to target drug-resistant cancer cells.
Targeting disorderly packed chromatin in cancer cell may improve their responses to treatments, Northwestern University scientists say.
Combining AZ's MCL1 inhibitor AZD5991 with existing MEK or BRAF inhibitors could kill melanoma cells more effectively, scientists found.
Cancer has always mirrored evolution, but now researchers are developing a new class of drug that blocks the mutations that lead to drug resistance.
The mezzanine round will fund ORIC's lead asset through phase 1b and into phase 2 and move a second program into the clinic.
The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors.
Deciphera aims to get ripretinib approved first as a fourth- and second-line treatment for GIST, but is not looking for a first-line approval.
A phosphor-binding site on aberrantly spliced BRAF V600E could become a new target against drug-resistant melanoma.
TP Therapeutics and Almac will collaborate on a pan-cancer companion diagnostic for TP’s repotrectinib aimed at drug-resistant tumors.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.